Cefotetan: a perspective for the surgical patient.
The data have shown that cefotetan has comparable clinical effectiveness when compared with cefoxitin in surgical prophylaxis and in patients with mild-to-moderate polymicrobial infection. This experience has consistently focused on the longer serum elimination half-life of cefotetan, which allows the antibiotic to be given less often than shorter half-life alternatives. A more extensive experience in seriously ill patients is necessary to further address 1) the use of cefotetan as an alternative to combination antibiotic therapy; 2) the risks of the anaerobic DOT group or enterococcal failure; and 3) potential clinical expression of any bleeding diathesis. The initial clinical experience reported herein appears favorable.